ResearcherUniversity of FreiburgActive in the last 2 years

Friederike Inga Nollmann

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5078543354. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Co-author DOI 10.1038/s41392-025-02563-7 ↗
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Co-author DOI 10.3390/biomedicines8080281 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dietrich Alexander Ruess · 2 shared papers, 2020–2026 · strength 0.44
- Paper Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? DOI 10.3390/biomedicines8080281 ↗
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗
Melanie Boerries · 1 shared paper, 2026 · strength 0.20
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗
Wilfried Reichardt · 1 shared paper, 2026 · strength 0.20
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗
Asma Y. Alrawashdeh · 1 shared paper, 2026 · strength 0.20
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗
Philipp Hafner · 1 shared paper, 2026 · strength 0.20
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗
Oliver Schilling · 1 shared paper, 2026 · strength 0.20
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗
Uwe A. Wittel · 1 shared paper, 2026 · strength 0.20
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.